Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 211-219

  Arthur, L M ^a   Turnbull, A K ^a   Renshaw, L ^a   Keys, J ^a   Thomas, J S ^a   Wilson, T R ^b   Lackner, M R ^b   Sims, A H ^a   Dixon, J M ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b GENENTECH INC   (United States)

Author keywords

Breast cancer; Endocrine; Mutation; PIK3CA; PTEN; Resistance

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC ALPHA SUBUNIT; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUTATION RATE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASMS, SECOND PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE;

EID: 84906058935     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3080-x     Document Type: Article

References (40)

1. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102(3):802-807
2. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70
3. Dunlap J et al (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120(2):409-418
4. Kalinsky K et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049-5059
5. Saal LH et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554-2559
6. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94(4):455-459
7. Campbell IG et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678-7681
8. Bachman KE et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8):772-775
9. Levine DA et al (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11(8):2875-2878
10. Hennessy BT et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-4124
11. Bartlett JM (2010) Biomarkers and patient selection for PI3 K/Akt/mTOR targeted therapies: current status and future directions. Clin Breast Cancer 10(Suppl 3):S86-S95
12. Campbell RA et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817-9824
13. Ma CX, Crowder RJ, Ellis MJ (2011) Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 76(8):750-752
14. Ellis MJ et al (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119(2):379-390
15. Baselga J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630-2637
16. Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. New Engl J Med 366(6):520-529
17. Aleskandarany MA et al (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122(1):45-53
18. Cuorvo LV et al (2013) PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch 464(1):85-93
19. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283-296
20. Shoman N et al (2005) Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Modern pathol 18(2):250-259
21. Perez-Tenorio G et al (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13(12):3577-3584
22. Kirkegaard T et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139-146
23. Tokunaga E et al (2006) Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast cancer 13(2):137-144
24. Kerdivel G, Flouriot G, Pakdel F (2013) Modulation of estrogen receptor alpha activity and expression during breast cancer progression. Vitam Horm 93:135-160
25. Toy W et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439-1445
26. Robinson DR et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446-1451
27. Aitken SJ et al (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21(6):1254-1261
28. Thompson AM et al (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res 12(6):R92
29. Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G (2014) Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 16:205
30. Gonzalez-Angulo AM et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093-1101
31. Dupont Jensen J et al (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667-677
32. Spoerke JM et al (2012) Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 18(24):6771-6783
33. Schlag P, Hoeppner C, Bristol A, Kaur N, Quashnick S, Ravirala R J Kramer, Negash M, Brophy V, Lee S, Soviero S (2013) A real-time PCR assay for the detection of PIK3CA mutations in formalin-fixed paraffin embedded tissue (FFPET) specimens of breast cancer (BC). [abstract]. Cancer Res 2013. In: Proceedings of the 104th Annual meeting of the american association for cancer research, 73(8 Suppl), p Abstract nr 4217
34. Barbareschi M et al (2012) PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch 461(2):129-139
35. Barbi S et al (2010) The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exonselectivity is a signature of cancer type. J Exp Clin Cancer Res 29:32
36. Barbareschi M et al (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13(20):6064-6069
37. Kandula M et al (2013) Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients. Asian Pac J Cancer Prev 14(9):5067-5072
38. Sanchez CG et al (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13(2):R21
39. Loi S et al (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107(22):10208-10213
40. Loi S et al (2013) PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS ONE 8(1):e53292